Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): A preliminary report Meeting Abstract
| Authors: | Yang, C.; Hirsh, V.; Cadranel, J.; Chen, Y.; Park, K.; Kim, S.; Chao, T.; Oberdick, M.; Shahidi, M.; Miller, V. |
| Abstract Title: | Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): A preliminary report |
| Meeting Title: | 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 27 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2009 May 29-Jun 2 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2009-05-20 |
| Start Page: | 422s |
| Language: | English |
| ACCESSION: | WOS:000276606605264 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2009.27.15_suppl.8062 |
| Notes: | Meeting Abstract: 8062 -- Source: Wos |
